TODAY’S PATENT – METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES

The said invention (US9084776B2) was invented by Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, and Haichun Huang. It was patented by USPTO on July 21^st, 2015. Currently, it stands assigned to Ono Pharmaceutical Co Ltd and ER Squibb & Sons LLC.

The current invention pertains to the use of anti-PD-1 antibodies and a combination of anti-CTLA-4 and anti-PD-1 antibodies in immunotherapy for the treatment of human illnesses, namely cancer. PD-1 is a receptor found on immune cells that, when it interacts with its ligands PD-L1 or PD-L2, hinders immune responses, enabling cancer cells to avoid being detected. This innovation offers distinct monoclonal antibodies that selectively attach to PD-1 with a strong attraction while avoiding any interaction with other members of the CD28 family such as CD28, CTLA-4, or ICOS. These antibodies efficiently regulate immune responses, augmenting the body’s capacity to specifically target and impede tumour development.

The invention seeks to enhance the effectiveness of cancer immunotherapy while minimizing the negative effects linked to specific antibody therapies, providing a new and efficient method for treating cancer.